---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-073492"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2022-11-17T23:59:59+00:00"
generated_at: "2026-06-21T16:43:42.208726+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# InMed terminates interim CFO Brenda Edwards; promotes Sarah Li to VP Accounting and Controller

## Summary
- Brenda Edwards' consulting agreement terminated effective Nov 20, 2022; she served as interim CFO since April 2022.
- Sarah Li promoted to VP of Accounting and Controller and Principal Accounting Officer; she was Controller since Jan 2020.
- Company in discussions to engage new interim financial leadership (CFO) consulting services.
- Press release issued Nov 17, 2022 providing management change update.

## SEC filing metadata
- accession: 0001213900-22-073492
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2022-11-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/0001213900-22-073492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/ea168928-8k_inmedpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-073492
- JSON: https://secwatch.observer/filing/0001213900-22-073492.json
- Plain text: https://secwatch.observer/filing/0001213900-22-073492.txt

## Key facts
- Executive change
  Sarah Li changed role as Vice President of Accounting and Controller and Principal Accounting Officer at InMed Pharmaceuticals Inc..
  - Action: promoted
  - Role: Vice President of Accounting and Controller and Principal Accounting Officer
  source text: The Company’s Controller, Sarah Li, has been promoted to Vice President of Accounting and Controller and Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/0001213900-22-073492-index.htm
- Executive change
  Brenda Edwards was terminated as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..
  - Action: terminated
  - Role: Interim Chief Financial Officer
  source text: On November 14, 2022, the Company terminated the Consulting Agreement for Brenda Edwards effective November 20, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022073492/0001213900-22-073492-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.